Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Notes Payables (2021 - 2023)

Historic Notes Payables for ImmunityBio (IBRX) over the last 5 years, with Q2 2023 value amounting to $481.9 million.

  • ImmunityBio's Notes Payables rose 6058.64% to $481.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $481.9 million, marking a year-over-year increase of 6058.64%. This contributed to the annual value of $431.9 million for FY2022, which is 4433.46% up from last year.
  • Per ImmunityBio's latest filing, its Notes Payables stood at $481.9 million for Q2 2023, which was up 6058.64% from $441.6 million recorded in Q1 2023.
  • ImmunityBio's 5-year Notes Payables high stood at $481.9 million for Q2 2023, and its period low was $299.2 million during Q4 2021.
  • Moreover, its 3-year median value for Notes Payables was $366.0 million (2022), whereas its average is $375.7 million.
  • As far as peak fluctuations go, ImmunityBio's Notes Payables skyrocketed by 4433.46% in 2022, and later surged by 6058.64% in 2023.
  • Over the past 3 years, ImmunityBio's Notes Payables (Quarter) stood at $299.2 million in 2021, then skyrocketed by 44.33% to $431.9 million in 2022, then increased by 11.58% to $481.9 million in 2023.
  • Its Notes Payables was $481.9 million in Q2 2023, compared to $441.6 million in Q1 2023 and $431.9 million in Q4 2022.